在使用主动学习细分管道的阿尔茨海默病中,状交叉体和tau之间的关联
Jiaxin Li1, Yueqin Hu2, Yunzhi Xu1
1College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China.
Fluids and barriers of the CNS
|July 12, 2024
概括
这项研究开发了一个精确的状交叉体细分管道,揭示了它与阿尔茨海默病 (AD) 中的tau水平的关联. 该管道在阿兹海默病患者中发现了较大的胆脉体积和更高的 perfusion,与tau生物标志物相关联.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物发现发现
- 计算病理学计算病理学
背景情况:
- 大脑脊髓液 (CSF) 由状交叉体 (ChP) 生产对于淋巴系统至关重要.
- 慢性脑膜功能的改变与阿尔茨海默氏症 (AD) 病原发生有关.
- 需要精确的CHP细分来研究其在AD中的作用.
研究的目的:
- 开发和验证一个新的ChP图像细分管道.
- 在阿尔茨海默病患者中调查CHP体积和血液流动.
- 探索CHP指标和AD CSF生物标志物之间的相关性.
主要方法:
- 通过使用主动学习来实现一个人-在-循环细分管道.
- 管道的性能与FreeSurfer和FastSurfer进行了评估.
- 在AD和对照组中分析了CHP体积和 perfusion.
- 回归模型评估了CHP指标和CSF生物标志物 (p-tau,t-tau,Aβ42,Aβ40) 之间的相关性.
主要成果:
- 拟议的管道实现了0.620的Dice系数,超过了现有的工具.
- 与对照组相比,AD患者表现出明显更大的CHP体积和更高的 perfusion.
- 在tau水平和相对CHP体积之间发现了显著的相关性.
- 粉样蛋白-β标记物与侧腔室测量结果有相关性.
结论:
- 开发的管道允许精确的CHP细分.
- 研究结果显示,在阿尔茨海默氏症中,ChP和tau病理之间存在显著的关联.
- 在GitHub上公开提供ChP细分管道.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
01:23Alzheimer Disease ll: Pathophysiology
21
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
21
01:22Dementia l: Introduction
29
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
29